尼莫地平片联合硫酸镁注射液治疗妊娠期高血压的临床研究

Clinical trial of nimodipine tablets combined with magnesium sulfate injection in the treatment of pregnancy induced hypertension

目的观察尼莫地平片联合硫酸镁注射液治疗妊娠期高血压的临床疗效及安全性。方法将92例妊娠期高血压患者随机分为对照组45例和试验组47例。对照组给予25%硫酸镁注射液每次20 m L,bid,静脉注射;试验组在对照组治疗的基础上,给予尼莫地平片每次30 mg,qd,口服。2组患者均治疗7 d。比较2组患者的临床疗效、血压,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为95. 74%(45例/47例)和82. 22%(37例/45例),差异有统计学意义(P <0. 05)。治疗后,试验组和对照组的收缩压分别为(123. 42±8. 93)和(132. 89±9. 24) mm Hg,舒张压分别为(80. 31±5. 58)和(86. 97±6. 56) mm Hg,差异均有统计学意义(P <0. 05)。2组患者发生的药物不良反应均以头晕、胃肠道不适和低血压为主。试验组和对照组的总药物不良反应发生率分别为12. 77%和13. 33%,差异无统计学意义(P> 0. 05)。结论尼莫地平片联合硫酸镁注射液治疗妊娠期高血压的临床效果确切,且不增加药物不良反应的发生率。

Objective To observe the clinical efficacy and safety of nimodipine tablets combined with magnesium sulfate injection in the treatment of pregnancy induced hypertension.Methods Ninety-two patients with pregnancy induced hypertension were divided into control group(n=45 cases)and treatment group(n=47 cases).Control group was given25%magnesium sulfate injection 20 m L,bid,intravenous injection.Treatment group was given nimodipine tablets 30 mg per time,qd,orally,on the basis of control group.Two groups were treated for 7 days.The clinical efficacy,blood pressure and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 95.74%(45 cases/47 cases)and 82.22%(37 cases/45 cases)with significant difference(P<0.05).After treatment,the main indexes of treatment and control groups were compared:the systolic blood pressure were(123.42±8.93)and(132.89±9.24)mm Hg,the diastolic blood pressure were(80.31±5.58)and(86.97±6.56)mm Hg,the differences were statistically significant(all P<0.05).The adverse drug reactions of two groups were dizziness,gastrointestinal discomfort and hypotension.The total incidences of adverse drug reactions in the treatment and control groups were 12.77%and 13.33%without significant difference(P>0.05).Conclusion Nimodipine tablets combined with magnesium sulfate injection have a definitive clinical efficacy in the treatment of pregnancy induced hypertension,without increasing the incidence of adverse drug reactions.